Also found in: Medical.
Related to medoxomil: azilsartan medoxomil


A univalent organic group, C5H5O3, chiefly used in combination with olmesartan as a prodrug.

[me(thyl) + d(i)- + oxo- + alteration of m(eth)yl.]
Mentioned in ?
References in periodicals archive ?
Contract notice: Open house drug contracts c09dx03 olmesartan medoxomil, Amlodipine and hydrochlorothiazide.
for one, this month introduced olmesartan medoxomil tablets, 5 mg, 20 mg and 40 mg.
M2 PHARMA-July 18, 2017-FDA approves Alembic Pharmaceuticals' ANDA for Olmesartan Medoxomil and Amlodipine tablets
Glenmark Pharmaceuticals has received final approval from the US health regulator for Amlodipine and Olmesartan Medoxomil tablets, used in the treatment of hypertension.
M2 EQUITYBITES-May 26, 2017-Glenmark Pharma gains US FDA approval for its blood pressure generic Olmesartan Medoxomil
2 -- Ajanta Pharma Limited, announces today US FDA* approval and launch of Amlodipine + Olmesartan Medoxomil Tablets in the US market through its wholly owned subsidiary Ajanta Pharma USA Inc.
7) Amlodipine, chlorthalidone, and azilsartan medoxomil, all of which have long half-lives, are approximately 50% more potent than other antihypertensive agents.
The novel angiotensin II receptor blocker azilsartan medoxomil ameliorates insulin resistance induced by chronic angiotensin II treatment in rat skeletal muscle," Cardiorenal Medicine, vol.
Olmesartan medoxomil (trade name Benicar), the prodrug of olmesartan, is an angiotensin II receptor blocker (ARB) that was approved for use in the United States as an antihypertensive medication in 2002.
5 mg/d; olmesartan medoxomil, 40 mg/d; aspirin, 81 mg/d; simvastatin, 10 mg/d; eszopidone, 3 mg at bedtime; and amlodipine, 5 mg at bedtime.
Azilsartan medoxomil plus chlorthalidone reduces BP more effectively than olmesartan plus HCTZ in stage 2 systolic hypertension [LB-OR-03].
This edition includes new drugs, including Azilsartan Medoxomil, Boceprevir, Clobazam, Ezogabine, Fidaxomicin, Linagliptin, Rilpivirine, Rivaroxaban, Telaprevir, Roflumilast, Ticagrelor, and Vilazodone; updated bisphosphonate, antipsychotic, carbapenem, and proton pump inhibitor group monographs; new combinations such as Emtricitabine/Rilpivirine/Tenofovir; and a revised ophthalmic/otic chapter with additions like glaucoma combinations, mast cell stabilizers, ophthalmic antihistamines, and otic corticosteroids.